Article Text

Download PDFPDF
Review: thiazolidinediones increase risk of heart failure in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

S Singh

Dr S Singh, Wake Forest University School of Medicine, Winston-Salem, NC, USA;



in patients with type 2 diabetes, what is the risk of heart failure (HF) associated with thiazolidinediones (TZDs)?

Search methods:

Medline (January 2003 to September 2006), EMBASE/Excerpta Medica, Google Scholar, Web of Knowledge, Canadian Drug Reaction Monitoring Program, reference lists, and manufacturers for unpublished studies.

Study selection and assessment:

randomised controlled trials (RCTs) in any language comparing TZDs (rosiglitazone [RGZ] or pioglitazone) with placebo for ⩾6 months in patients with type 2 diabetes and HF; cohort or case-control studies comparing TZDs with other oral antidiabetic drugs (with or without insulin) for new-onset HF; and case reports or case series of all adverse drug reactions (HF and pulmonary oedema) of TZDs. {Quality assessment of individual studies was based on the definition of HF and ascertainment of HF …

View Full Text


  • Source of funding: no external funding.